Have a personal or library account? Click to login
Development of bioflavonoid containing chemotherapeutic delivery systems for UV-damaged skin and kangri cancer Cover

Development of bioflavonoid containing chemotherapeutic delivery systems for UV-damaged skin and kangri cancer

Open Access
|Oct 2022

Figures & Tables

Figure 1

Phase diagram of 1:1 weight ratio of microemulsion.
Phase diagram of 1:1 weight ratio of microemulsion.

Figure 2

Phase diagram of 2:1 weight ratio of microemulsion.
Phase diagram of 2:1 weight ratio of microemulsion.

Figure 3

Phase diagram of 3:1 weight ratio of microemulsion.
Phase diagram of 3:1 weight ratio of microemulsion.

Figure 4

Transmission electron microscopic surface area of prepared microemulsion batches.
Transmission electron microscopic surface area of prepared microemulsion batches.

Figure 5

Viscosity of microemulsion batches.
Viscosity of microemulsion batches.

Figure 6

Graph of pH values of microemulsion batches.
Graph of pH values of microemulsion batches.

Figure 7

Globules size range of prepared microemulsion batches.
Globules size range of prepared microemulsion batches.

Figure 8

Comparative skin retention profile for the all the formulation 5-FU
Comparative skin retention profile for the all the formulation 5-FU

Figure 9

Percentage (%) mean cumulative 5-FU microemulsions penetration in skin.
Percentage (%) mean cumulative 5-FU microemulsions penetration in skin.

Figure 10

Acute skin irritation test of prepared microemulsion batches (a) RME 1, (b) RME 2, (c) RME 3 and control (d).
Acute skin irritation test of prepared microemulsion batches (a) RME 1, (b) RME 2, (c) RME 3 and control (d).

pH of prepared microemulsion batches_

Batch no.pH
RME15.24
RME25.93
RME35.67

Ingredients list for preparation of FU microemulsion_

IngredientProperty
5-FUDrug
Tween 20Surfactant
Isopropyl alcoholCosurfactant
Isopropyl myristateOil
DMSOPenetration enhancer
RutinAntioxidant

Values of drug permeation of prepared microemulsion batches_

Time5-FURME1RME2RME3

AbsorptionAbsorptionAbsorptionAbsorption
0 min0.1280.1280.1350.138
1 min0.1300.1450.1520.156
2 min0.1610.1650.1740.178
3 min0.1820.1930.2030.208
4 min0.2170.2320.2440.251
5 min0.2750.2910.3050.312
10 min0.3580.3860.4060.416
30 min0.5100.5810.610.625
60 min1.0121.1611.221.25
3 hours1.0121.1611.221.25

Solubility of R-5FU in different oils, surfactants and co-surfactants_

OilSolubility(mg/ml)

Isopropyl myristate165.28
Oleic acid183.12
Castor oil44.26
Olive oil32.61

SurfactantSolubility (mg/ml)

Tween 80105.28
Tween 2093.12
Span 8058.27
Span 2031.62

CosurfactantSolubility (mg/ml)

Isopropyl alcohol107.28
Ethanol43.12
N-butanol58.27
Polyethylene glycol69.62
Propylene glycol79.62

Scoring for irritation testing (HET-CAM assay)_

Test formulationEffectScore
Net scoreInference
0.5 min2 min5 min
RME1Lysis------0Non-irritant
Hemorrhage------
Coagulation------
RME2Lysis-----0Non-irritant
Hemorrhage------
Coagulation------
RME3Lysis------0Non-irritant
Hemorrhage------
Coagulation------
Control (0.9%NaCl)Lysis------0non-irritant
Hemorrhage------
Coagulation------
Irritant (0.1 N NaOH)Lysis--7--23Severe-irritant
Hemorrhage7----
Coagulation9----

Effects of RME1, RME2, RME3, control and irritant on chorioallantoic membrane with different time interval_

Time: -
0.5 minutes2 minutes5 minutes
Groups: -
RME1
RME2
RME3
Control
Irritant

Mean erythemal score evaluated for different formulation_

Erythemal Score (n-6)
Days25710141821
Control0000000
RME10000001
RME20000011
RME30000011
Formalin (0.8%)0011233

Viscosity of prepared microemulsion batches_

Batch no.Viscosity
RME114.68
RME216.52
RME317.25
DOI: https://doi.org/10.2478/fco-2021-0012 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Language: English
Page range: 86 - 98
Submitted on: Nov 6, 2021
Accepted on: Jan 26, 2022
Published on: Oct 23, 2022
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year

© 2022 Harish Sharma, Gyanesh Kumar Sahu, Chanchal Deep Kaur, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.